Niagen Bioscience
 | |
| Company type | Public |
|---|---|
| Nasdaq: NAGE Russell 2000 Index component | |
| Industry | Dietary supplements, food ingredients, chemical sample analysis |
| Founded | 1999 |
| Headquarters | Los Angeles, California, United States |
Key people | Rob Fried (CEO) Frank Jaksch (Cofounder, Executive Chairman) |
| Products | Tru Niagen Niagen Plus |
| Website | https://www.niagenbioscience.com/ |
Niagen Bioscience (NASDAQ: NAGE), formerly ChromaDex, is a bioscience сompany based in Los Angeles, California founded in 1999.[1] The company operates in multiple sectors including reference standards, dietary supplements, and ingredient technology.[2] Niagen Bioscience is publicly traded on the NASDAQ.[3]
History
[edit]Founded in 1999 by Frank Jaksch, ChromaDex began as a standards company serving the natural products industry.[4] The company expanded its operations by acquiring licensed patents from Dartmouth College, Cornell University, and Washington University in St. Louis regarding nicotinamide riboside, which it markets and sells as an ingredient under the brand name Niagen.[5]
In 2015, Robert "Rob" Fried joined ChromaDex's board of directors.[6]
Niagen Bioscience is traded on the NASDAQ (as NAGE), as of March 2025,[7] and was added to the U.S. Small Cap Russell 2000 Index in June 2018.
In March 2017, the company acquired HealthSpan Research LLC and its product Tru Niagen, a standalone nicotinamide riboside supplement, sold directly to U.S. consumers.[8] Following this acquisition, Rob Fried was appointed president and Chief Operating Officer of ChromaDex.[9]
Also in 2017, ChromaDex raised $48 million to support research and development.[10]
In April 2018, Rob Fried was appointed chief executive officer of ChromaDex, succeeding Frank Jaksch, who transitioned to the position of Executive Chairman.[11]
On March 19, 2025, ChromaDex, Corp. was officially renamed Niagen Bioscience.[7]
Research and development
[edit]ChromaDex has invested in research on nicotinamide riboside and its role in increasing NAD+ levels in the body. The company has partnered with multiple research institutions, such as the National Institutes of Health, the Biotechnology and Biological Sciences Research Council, and Northwestern University Feinberg School of Medicine, to study the potential benefits of nicotinamide riboside on various aspects of health and aging.[12][13]
In April 2018, Rob Fried was appointed chief executive officer of ChromaDex, succeeding Frank Jaksch, who transitioned to the position of Executive Chairman.[11] As of 2025, ChromaDex has supported over 35 human clinical studies investigating the safety, efficacy, and benefits of Niagen (nicotinamide riboside chloride).[14]
References
[edit]- ^ "ChromaDex rebrands as Niagen Bioscience to reflect growth in supplement, pharmaceutical industries". NutraIngredients-USA.com. 2025-03-17. Retrieved 2025-03-20.
- ^ "Search". MarketWatch. Retrieved 2025-03-20.
- ^ "ChromaDex Corporation (CDXC) Stock Price, Quote & News". Nasdaq. Retrieved 2025-03-20.
- ^ "ChromaDex, Inc.'s Founder, Frank Jaksch, Appears as an Industry Expert on "Dateline NBC"". BioSpace. 2012-03-19. Retrieved 2025-03-20.
- ^ "ChromaDex Licenses Exclusive Patent Rights for Nicotinamide Riboside (NR) Vitamin Technologies". www.nutritioninsight.com. Retrieved 2025-03-20.
- ^ "Niagen Bioscience (DB:OCD1) - Stock Price, News & Analysis". Simply Wall St. Retrieved 2025-03-20.
- ^ a b "ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025". Yahoo Finance. Business Wire. March 13, 2025. Retrieved March 19, 2025.
- ^ staff-author (2017-09-03). "ChromaDex Shifts to Direct-to-Consumer Model". Orange County Business Journal. Retrieved 2025-03-20.
{{cite web}}:|last=has generic name (help) - ^ "ChromaDex Corporation 2017 Annual Report" (PDF). AnnualReports.com. Retrieved 2025-03-20.
- ^ "ChromaDex raises another $23 million via private offering". NutraIngredients-USA.com. 2017-11-07. Retrieved 2025-03-20.
- ^ a b "Profile of Robert N Fried". Bloomberg. Retrieved 2025-03-18.
- ^ "First human clinical trial for nicotinamide riboside | Carver College of Medicine". medicine.uiowa.edu. Retrieved 2025-03-20.
- ^ "Milestone Phase II Clinical Study Demonstrates Niagen, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD)". Neuro Central. 2024-06-24. Retrieved 2025-03-20.
- ^ user, HPAchina (2024-02-27). "Review Paper in Science Advances Discusses Reduced Inflammation and Increased NAD+ - HPACHINA". Retrieved 2025-03-20.
{{cite web}}:|last=has generic name (help)
